https://www.selleckchem.com/pr....oducts/bay-2666605.h
Predictors of a higher relapse rate in the first year were younger age at fingolimod cessation, higher relapse rate in the year prior to cessation, delaying commencement of new therapy and switching to low-efficacy therapy. Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation and in those who switch to a low-efficacy therapy. Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activ
Like
Comment
Share
